Francisco José Román-Rodriguez

Francisco José Román-Rodriguez

Auto-generated profile, based on publicly available information

Francisco José Román-Rodriguez

Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PRPaula Rio
Paula Rio
SNSusana Navarro
Susana Navarro
WWWei Wang
Wei Wang
RSRebeca Sánchez-Domínguez
Rebeca Sánchez-Domínguez
RPRoser M. Pujol
Roser M. Pujol
JBJuan A Bueren
Juan A Bueren

1 November 2019 in Cell Stem Cell
Verified
Journal Article
Closed access
FRFrancisco José Román-Rodríguez
Francisco José Román-Rodríguez
LULaura Ugalde
Laura Ugalde
LÁLara Álvarez
Lara Álvarez
BDBegoña Díez
Begoña Díez
MRMaría José Ramírez
María José Ramírez
PRPaula Rio
Paula Rio

12 September 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
BDBegoña Diez
Begoña Diez
PGPietro Genovese
Pietro Genovese
FRFrancisco J Roman‐Rodriguez
Francisco J Roman‐Rodriguez
LALara Alvarez
Lara Alvarez
GSGiulia Schiroli
Giulia Schiroli
PRPaula Rio
Paula Rio
Gene targeting constitutes a new step in the development of gene therapy for inherited diseases. Although previous studies have shown the feasibility of editing fibroblasts from Fanconi anemia (FA) patients, here we aimed at conducting therapeutic gene editing in clinically relevant cells, such as hematopoietic stem cells (HSCs). In our first experiments, we showed that zinc finger nuclease (ZFN)‐mediated insertion of a non‐therapeutic EGFP‐reporter donor in the AAVS1 “safe harbor” locus of FA‐A lymphoblastic cell lines (LCLs), indicating that FANCA is not essential for the editing of human cells. When the same approach was conducted with therapeutic FANCA donors, an efficient phenotypic correction of FA‐A LCLs was obtained. Using primary cord blood CD34+ cells from healthy donors, gene targeting was confirmed not only in in vitro cultured cells, but also in hematopoietic precursors responsible for the repopulation of primary and secondary immunodeficient mice. Moreover, when similar experiments were conducted with mobilized peripheral blood CD34+ cells from FA‐A patients, we could demonstrate for the first time that gene targeting in primary hematopoietic precursors from FA patients is feasible and compatible with the phenotypic correction of these clinically relevant cells. Synopsis Zinc finger nuclease‐mediated gene editing facilitates insertion of a therapeutic gene in the AAVS1 “safe harbor” locus in human hematopoietic cell lines and primary HSPCs from healthy donors and patients with Fanconi anemia‐A, leading to their phenotypic correction. FANCA is not essential for zinc finger nuclease (ZFN)‐mediated gene editing in human hematopoietic cells. ZFN‐mediated gene editing facilitates the targeting of FANCA in a “safe harbor” locus of lymphoblastic cell lines (LCLs) from Fanconi anemia A (FA‐A) patients. ZFN‐mediated gene editing facilitates the targeting of donor constructs in long term hematopoietic stem and progenitor cells (HSPCs) from healthy donors. Gene targeting of therapeutic constructs in HSPCs from FA‐A patients is thus feasible and mediates the phenotypic correction of these cells.

24 October 2017 in Blood Advances
Verified
Journal Article
Closed access
PDF file
CLCamille Lévy
Camille Lévy
FAFouzia Amirache
Fouzia Amirache
AGAnais Girard-Gagnepain
Anais Girard-Gagnepain
CFCecilia Frecha
Cecilia Frecha
FRFrancisco J. Roman-Rodríguez
Francisco J. Roman-Rodríguez
Els VerhoeyenEls Verhoeyen
Els Verhoeyen
Hematopoietic stem cell (HSC)–based gene therapy trials are now moving toward the use of lentiviral vectors (LVs) with success. However, one challenge in the field remains: efficient transduction of HSCs without compromising their stem cell potential. Here we showed that measles virus glycoprotein–displaying LVs (hemagglutinin and fusion protein LVs [H/F-LVs]) were capable of transducing 100% of early-acting cytokine-stimulated human CD34+ (hCD34+) progenitor cells upon a single application. Strikingly, these H/F-LVs also allowed transduction of up to 70% of nonstimulated quiescent hCD34+ cells, whereas conventional vesicular stomatitis virus G (VSV-G)–LVs reached 5% at the most with H/F-LV entry occurring exclusively through the CD46 complement receptor. Importantly, reconstitution of NOD/SCIDγc−/− (NSG) mice with H/F-LV transduced prestimulated or resting hCD34+ cells confirmed these high transduction levels in all myeloid and lymphoid lineages. Remarkably, for resting CD34+ cells, secondary recipients exhibited increasing transduction levels of up to 100%, emphasizing that H/F-LVs efficiently gene-marked HSCs in the resting state. Because H/F-LVs promoted ex vivo gene modification of minimally manipulated CD34+ progenitors that maintained stemness, we assessed their applicability in Fanconi anemia, a bone marrow (BM) failure with chromosomal fragility. Notably, only H/F-LVs efficiently gene-corrected minimally stimulated hCD34+ cells in unfractionated BM from these patients. These H/F-LVs improved HSC gene delivery in the absence of cytokine stimulation while maintaining their stem cell potential. Thus, H/F-LVs will facilitate future clinical applications requiring HSC gene modification, including BM failure syndromes, for which treatment has been very challenging up to now. Key Points H/F-LVs permit very-high-level transduction of human HSCs, even in the complete absence of cytokine stimulation. H/F-LVs outperform VSV-G-LVs for efficient correction of Fanconi anemia patient cells in unfractionated BM. Visual Abstract

1 September 2014 in Genetics in Medicine
Verified
Journal Article
Closed access
ATAna Torroglosa
Ana Torroglosa
MEMaría Valle Enguix-Riego
María Valle Enguix-Riego
RFRaquel María Fernández
Raquel María Fernández
FRFrancisco José Román-Rodriguez
Francisco José Román-Rodriguez
MMMaría José Moya-Jiménez
María José Moya-Jiménez
SBSalud Borrego
Salud Borrego

5 December 2013 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
RFRaquel M. Fernández
Raquel M. Fernández
RNRaquel Núñez‐Ramos
Raquel Núñez‐Ramos
MEMª Valle Enguix‐Riego
Mª Valle Enguix‐Riego
FRFrancisco José Román‐Rodríguez
Francisco José Román‐Rodríguez
EGEnrique Galán‐Gómez
Enrique Galán‐Gómez
SBSalud Borrego
Salud Borrego